A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
TerminatedPhase 2NCT01056315
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
Study details
- Official title
- A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared to Placebo in Subjects With Painful Diabetic Peripheral Neuropathy
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- Drug: GRT3938Y
- Drug: Placebo
- Sponsor
- Grünenthal GmbH
- Start date
- 2009-11
- Primary completion
- 2011-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 61
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Symmetrical painful diabetic peripheral neuropathy Exclusion Criteria: * History of hypersensitivity, allergy or contraindication to opioids and acetaminophen * Confounding painful conditions * Significant vascular disease * History or risk of seizure * Chronic disease that might effect drug absorption, distribution, metabolism, or excretion * Female subjects who are being pregnant or breastfeeding * Evidence or history of alcohol, medication, or drug abuse
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01056315